Sen-lin Ji
Nanjing, 210008, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Novel natural inhibitor Rubimaillin targets NLRP3 R167/Y381 to ameliorate inflammatory and neurodegenerative diseases.
Journal: Journal of ethnopharmacology
Published: May 19, 2026
Carabrone alleviates neuroinflammation by covalently targeting ubiquitin conjugating enzyme UBE2D3 in experimental autoimmune encephalomyelitis.
Journal: European journal of pharmacology
Published: January 23, 2026
Corrigendum to "Broxyquinoline targets NLRP3 to inhibit inflammasome activation and alleviate NLRP3-associated inflammatory diseases" [Int. Immunopharmacol. 156 (2025) 114687].
Journal: International immunopharmacology
Published: November 23, 2025
High-Throughput Screening Reveals That CeeNU Acts as a New NLRP3 Inflammasome Inhibitor.
Journal: MedComm
Published: October 09, 2024
Broxyquinoline targets NLRP3 to inhibit inflammasome activation and alleviate NLRP3-associated inflammatory diseases.
Journal: International immunopharmacology
Published: September 18, 2024
Gastrodenol suppresses NLRP3/GSDMD mediated pyroptosis and ameliorates inflammatory diseases.
Journal: Cellular immunology
Published: June 13, 2024
New applications of clioquinol in the treatment of inflammation disease by directly targeting arginine 335 of NLRP3.
Journal: Journal of pharmaceutical analysis
Published: May 09, 2024
Showing 1-8 of 8
Last Updated: 09/26/2026